Martin Hutchings

Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial

Introduction:More tolerable, readily available treatment options are needed for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) to induce deep, durable responses. ...

Michael Roost Clausen ;

Mariana Sacchi ;

Catherine Thieblemont ;

Martin Hutchings ;

Tycel Phillips ;

Pieternella Lugtenburg ;

Herve Ghesquieres ;

Chan Y. Cheah ;

Young R. Do ;

Tatyana Feldman ;

Robin Gasiorowski ;

Wojciech Jurczak ;

Tae Min Kim ;

David J. Lewis ;

Mariolein van der Poe ;

Michelle L. Poon ;

Thomas Doerr ;

Nurgul Kilavuz ;

David Cunningham ;

Menghui Chen ;

11/04/2022

Martin Hutchings, MD, PhD, Rigshospitalet, Copenhagen

Videos

Glofitamab Plus Polatuzumab Vedotin Shows Frequent, Durable Responses and Manageable Safety Among Patients With R/R DLBCL

12/12/2023

Martin Hutchings ;

At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...

At the 65th ASH Annual Meeting,...

12/12/2023

Oncology